Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 3, 2013Journal of Nuclear MedicineOpen Access

Diels–Alder Reaction for Tumor Pretargeting: In Vivo Chemistry Can Boost Tumor Radiation Dose Compared with Directly Labeled Antibody

View Full Paper
Ask AI
Bookmark
Share

Authors

RRRaffaella RossinTagworks Pharmaceuticals (Netherlands)TLTilman LäppchenNXP (Netherlands)SBSandra M. van den BoschNXP (Netherlands)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Rossin et al. (2013) studied this question.

synapsesocial.com/papers/6a7ed4eccb17bc2d1d0d2aeahttps://doi.org/10.2967/jnumed.113.123745
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Rates and Equilibria for Probe Capture by an Antibody with Infinite Affinity2010 · 12 citations
  2. 2Bispecific Antibody Pretargeting of Tumor Neovasculature for Improved Systemic Radiotherapy of Solid Tumors2006 · 38 citations
  3. 3Bioorthogonal Chemistry: Fishing for Selectivity in a Sea of Functionality2009 · 3,193 citations
  4. 4Improved Therapeutic Results by Pretargeted Radioimmunotherapy of Non–Hodgkin's Lymphoma with a New Recombinant, Trivalent, Anti-CD20, Bispecific Antibody2008 · 75 citations